Turn Therapeutics (NASDAQ:TTRX) Releases Earnings Results

Turn Therapeutics (NASDAQ:TTRX) released its quarterly earnings data on Monday. The company reported ($0.03) EPS for the quarter, FiscalAI reports.

Turn Therapeutics Trading Up 2.4%

Turn Therapeutics stock traded up $0.09 during midday trading on Monday, hitting $3.88. 9,215 shares of the company were exchanged, compared to its average volume of 29,068. The company has a market cap of $115.59 million and a P/E ratio of -24.25. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50. The stock has a fifty day simple moving average of $3.48.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. DDFG Inc grew its holdings in Turn Therapeutics by 34.9% during the 1st quarter. DDFG Inc now owns 70,534 shares of the company’s stock valued at $226,000 after purchasing an additional 18,246 shares in the last quarter. XTX Topco Ltd acquired a new position in Turn Therapeutics in the 4th quarter worth $99,000. Millennium Management LLC purchased a new position in Turn Therapeutics in the 4th quarter valued at about $377,000. Tamar Securities LLC acquired a new stake in shares of Turn Therapeutics during the fourth quarter valued at about $59,000. Finally, Jane Street Group LLC acquired a new stake in shares of Turn Therapeutics during the fourth quarter valued at about $68,000.

Wall Street Analyst Weigh In

Separately, D. Boral Capital restated a “buy” rating and issued a $8.00 price objective on shares of Turn Therapeutics in a report on Tuesday, March 24th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Turn Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.